Tyra Biosciences, Inc. (TYRA) Bundle
An Overview of Tyra Biosciences, Inc. (TYRA)
General Summary of Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. is a precision oncology company focused on developing targeted therapies for genomically defined cancers. Founded in 2017 and headquartered in South San Francisco, California.
Company Products and Services
Primary focus areas include:
- Precision oncology therapeutics
- Genomic cancer treatment development
- Targeted therapy research
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $18.4 million |
| Net Loss | ($93.5 million) |
| Research & Development Expenses | $71.2 million |
| Cash and Cash Equivalents | $285.6 million |
Key Pipeline Information
Current clinical-stage programs:
- TYRA-1501: FGFR-selective inhibitor
- TYRA-2510: CDK4/6 inhibitor
Industry Leadership Indicators
Key Competitive Advantages:
- Proprietary precision oncology platform
- Advanced genomic targeting technologies
- Focused clinical development strategy
Stock Performance
| Stock Symbol | NASDAQ: TYRA |
|---|---|
| IPO Date | July 22, 2021 |
| Current Share Price (as of 2024) | $7.23 |
Mission Statement of Tyra Biosciences, Inc. (TYRA)
Mission Statement Overview
Tyra Biosciences, Inc. (TYRA) mission statement focuses on precision oncology and targeted cancer therapies.
Mission Statement Components
| Component | Specific Details |
|---|---|
| Research Focus | Developing targeted therapies for genomically defined cancers |
| Scientific Approach | Precision oncology targeting specific genetic mutations |
| Patient Impact | Improving cancer treatment outcomes through personalized medicine |
Research and Development Strategy
Tyra Biosciences has $94.2 million in research and development expenses as of Q3 2023.
- Primary research platforms targeting FGFR and EGFR genetic alterations
- Developing small molecule inhibitors for cancer treatment
- Focus on precision oncology therapeutic approaches
Key Scientific Priorities
| Priority Area | Current Investment |
|---|---|
| FGFR Inhibitor Development | $42.7 million allocated in 2023 |
| Genomic Cancer Research | 37% of total R&D budget |
Clinical Pipeline Metrics
Current clinical pipeline includes 3 active therapeutic programs targeting specific genetic mutations.
- TYRA-1501: Phase 1/2 clinical trial for FGFR-altered cancers
- Total active clinical trials: 2 ongoing studies
- Projected patient enrollment: 120 patients across current trials
Financial Commitment to Mission
Tyra Biosciences reported $156.3 million in total funding as of December 2023.
| Funding Source | Amount |
|---|---|
| Venture Capital | $98.6 million |
| Research Grants | $22.4 million |
Vision Statement of Tyra Biosciences, Inc. (TYRA)
Vision Statement Components of Tyra Biosciences, Inc. (TYRA)
Precision Oncology FocusTyra Biosciences aims to develop targeted therapies for patients with genomically defined cancers. As of Q4 2023, the company's research pipeline targets specific genetic mutations in cancer treatment.
| Research Area | Target Mutation | Development Stage |
|---|---|---|
| FGFR Inhibition | FGFR1/2/3 Alterations | Phase 2 Clinical Trials |
The company concentrates on developing small molecule inhibitors addressing complex genetic alterations in cancer.
- Research investment: $42.3 million in 2023
- Active clinical programs: 3 primary molecular targeting initiatives
- Patent portfolio: 17 granted patents
Tyra Biosciences prioritizes developing therapies for patient populations with limited treatment options.
| Therapeutic Area | Patient Population | Unmet Medical Need |
|---|---|---|
| Solid Tumors | Genomically Defined Cancers | High Molecular Complexity |
Tyra collaborates with leading research institutions to accelerate therapeutic discovery.
- Academic partnerships: 5 active research collaborations
- Scientific advisory board: 7 distinguished oncology experts
Core Values of Tyra Biosciences, Inc. (TYRA)
Core Values of Tyra Biosciences, Inc. (TYRA)
Innovation and Scientific Excellence
Tyra Biosciences demonstrates commitment to innovation through substantial R&D investments. As of Q4 2023, the company allocated $42.3 million to research and development, representing 68% of total operating expenses.
| R&D Metric | 2023 Value |
|---|---|
| Total R&D Expenditure | $42.3 million |
| R&D as % of Operating Expenses | 68% |
| Active Research Programs | 7 distinct oncology programs |
Patient-Centric Approach
Tyra Biosciences prioritizes patient outcomes through targeted therapeutic development.
- Focused on precision oncology targeting specific genetic mutations
- Clinical trials addressing unmet medical needs
- Personalized treatment strategy development
Collaborative Scientific Ecosystem
The company maintains strategic partnerships with research institutions.
| Partnership Type | Number of Collaborations |
|---|---|
| Academic Research Partnerships | 4 |
| Pharmaceutical Collaborations | 2 |
| Total Research Collaborations | 6 |
Ethical and Transparent Operations
Tyra Biosciences maintains rigorous compliance standards.
- 100% compliance with FDA regulatory requirements
- Comprehensive clinical trial transparency protocols
- Independent ethics review board engagement
Sustainable Scientific Progress
The company's financial metrics reflect sustainable growth trajectory.
| Financial Metric | 2023 Value |
|---|---|
| Cash and Cash Equivalents | $218.5 million |
| Net Loss | $87.2 million |
| Research Pipeline Value | Estimated $750 million |
Tyra Biosciences, Inc. (TYRA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.